Merck & Co. Inc. Takes $88.54 Million Position in Kymera Therapeutics, Inc. $KYMR

Merck & Co. Inc. purchased a new stake in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund purchased 772,165 shares of the company’s stock, valued at approximately $88,544,161. Kymera Therapeutics accounts for approximately 0.0% of Merck & Co. Inc.’s holdings, making the stock its 3rd biggest position. Merck & Co. Inc. owned about 0.94% of Kymera Therapeutics as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also bought and sold shares of KYMR. Baker BROS. Advisors LP lifted its holdings in Kymera Therapeutics by 30.2% during the 4th quarter. Baker BROS. Advisors LP now owns 8,657,242 shares of the company’s stock valued at $673,620,000 after buying an additional 2,005,813 shares in the last quarter. Avoro Capital Advisors LLC boosted its holdings in Kymera Therapeutics by 17.7% in the fourth quarter. Avoro Capital Advisors LLC now owns 7,474,747 shares of the company’s stock valued at $581,610,000 after purchasing an additional 1,124,747 shares in the last quarter. Vanguard Group Inc. raised its holdings in Kymera Therapeutics by 15.6% during the fourth quarter. Vanguard Group Inc. now owns 6,267,644 shares of the company’s stock worth $487,685,000 after purchasing an additional 845,922 shares in the last quarter. Price T Rowe Associates Inc. MD increased its position in Kymera Therapeutics by 20.8% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 6,159,335 shares of the company’s stock worth $479,258,000 after purchasing an additional 1,061,957 shares in the last quarter. Finally, BlackRock Inc. acquired a new position in shares of Kymera Therapeutics during the 2nd quarter valued at $635,067,000.

Analyst Ratings Changes

Several equities research analysts recently commented on KYMR shares. BTIG Research restated a “buy” rating and issued a $134.00 price target on shares of Kymera Therapeutics in a research report on Thursday, June 25th. Mizuho upped their price objective on Kymera Therapeutics from $120.00 to $140.00 and gave the company an “outperform” rating in a report on Thursday, July 16th. Wall Street Zen raised Kymera Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, May 2nd. B. Riley Financial lifted their price objective on shares of Kymera Therapeutics from $117.00 to $155.00 and gave the company a “buy” rating in a research note on Monday, June 29th. Finally, Canaccord Genuity Group lifted their target price on shares of Kymera Therapeutics from $106.00 to $129.00 and gave the company a “buy” rating in a research note on Friday, June 26th. One research analyst has rated the stock with a Strong Buy rating, twenty have assigned a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $127.17.

Insiders Place Their Bets

In related news, CEO Nello Mainolfi sold 50,000 shares of the business’s stock in a transaction dated Tuesday, July 7th. The stock was sold at an average price of $119.00, for a total value of $5,950,000.00. Following the sale, the chief executive officer directly owned 666,568 shares in the company, valued at approximately $79,321,592. The trade was a 6.98% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Bvf Partners L. P/Il sold 1,578,800 shares of the company’s stock in a transaction that occurred on Friday, June 26th. The shares were sold at an average price of $106.50, for a total value of $168,142,200.00. Following the transaction, the director directly owned 240,123 shares of the company’s stock, valued at $25,573,099.50. The trade was a 86.80% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 3,587,629 shares of company stock worth $386,183,782 in the last ninety days. 15.98% of the stock is owned by insiders.

Kymera Therapeutics Stock Performance

Shares of KYMR stock traded down $1.23 during mid-day trading on Friday, hitting $119.00. 142,385 shares of the stock were exchanged, compared to its average volume of 735,087. Kymera Therapeutics, Inc. has a 12-month low of $39.84 and a 12-month high of $130.05. The stock has a market capitalization of $9.89 billion, a price-to-earnings ratio of -36.73 and a beta of 1.95. The stock’s fifty day simple moving average is $112.23 and its two-hundred day simple moving average is $93.44.

Kymera Therapeutics (NASDAQ:KYMR) last released its quarterly earnings data on Wednesday, August 5th. The company reported ($0.62) EPS for the quarter, beating the consensus estimate of ($0.71) by $0.09. The company had revenue of $65.00 million for the quarter, compared to analyst estimates of $32.78 million. Kymera Therapeutics had a negative return on equity of 21.22% and a negative net margin of 285.33%.The firm’s revenue was up 465.2% compared to the same quarter last year. During the same period last year, the company posted ($0.95) earnings per share. On average, research analysts expect that Kymera Therapeutics, Inc. will post -3.78 earnings per share for the current fiscal year.

About Kymera Therapeutics

Kymera Therapeutics, Inc is a clinical?stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small?molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease?causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.